- Home
- INTA vs PRAX Comparison
INTA vs PRAX Comparison
Compare INTA & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTA
- PRAX
- Stock Information
- Founded
- INTA 2000
- PRAX 2015
- Country
- INTA United States
- PRAX United States
- Employees
- INTA N/A
- PRAX N/A
- Industry
- INTA Computer Software: Prepackaged Software
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- INTA Technology
- PRAX Health Care
- Exchange
- INTA Nasdaq
- PRAX Nasdaq
- Market Cap
- INTA 3.5B
- PRAX 4.0B
- IPO Year
- INTA 2021
- PRAX 2020
- Fundamental
- Price
- INTA $41.55
- PRAX $195.82
- Analyst Decision
- INTA Buy
- PRAX Strong Buy
- Analyst Count
- INTA 9
- PRAX 12
- Target Price
- INTA $59.63
- PRAX $212.42
- AVG Volume (30 Days)
- INTA 732.5K
- PRAX 760.0K
- Earning Date
- INTA 11-04-2025
- PRAX 11-05-2025
- Dividend Yield
- INTA N/A
- PRAX N/A
- EPS Growth
- INTA N/A
- PRAX N/A
- EPS
- INTA N/A
- PRAX N/A
- Revenue
- INTA $524,342,000.00
- PRAX $7,463,000.00
- Revenue This Year
- INTA $15.18
- PRAX N/A
- Revenue Next Year
- INTA $13.48
- PRAX $44.43
- P/E Ratio
- INTA N/A
- PRAX N/A
- Revenue Growth
- INTA 17.11
- PRAX 364.98
- 52 Week Low
- INTA $35.51
- PRAX $26.70
- 52 Week High
- INTA $77.74
- PRAX $206.71
- Technical
- Relative Strength Index (RSI)
- INTA 56.20
- PRAX 67.37
- Support Level
- INTA $41.16
- PRAX $175.79
- Resistance Level
- INTA $43.62
- PRAX $188.53
- Average True Range (ATR)
- INTA 1.66
- PRAX 13.68
- MACD
- INTA 0.53
- PRAX -3.56
- Stochastic Oscillator
- INTA 72.70
- PRAX 81.28
About INTA Intapp Inc.
Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital,g, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.